Corbus Pharmaceuticals Holdings Inc
CRBP
Market Cap$114.83M
Close$
$1.28
87.2% downside
Current Fair Value
87.2% downsideOvervalued by 87.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $114.83 Million |
|---|---|
| Enterprise Value | $97.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 3.21 |
| Outstanding Shares | 12,240,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.98 |
|---|---|
| PEG | -2.58 |
| Price to Sales | - |
| Price to Book Ratio | 1.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.42 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...